2 not yet recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 2 |
Follow Guliz Ozgun: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. Nivolumab & Ipilimumab, Nivolumab + Ipilimumab - Advanced Kidney Cancer | Phase 3 | Not yet recruiting | Guliz Ozgun | 142 | 2027-02-01 | 2026-10-01 |
| The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer enfortumab vedotin and pembrolizumab (EV/P) - Advanced Bladder Cancer | Phase 3 | Not yet recruiting | Guliz Ozgun | 224 | 2026-11-01 | 2026-10-01 |
Ipilimumab (1) · Nivolumab (1) · enfortumab vedotin (1) · pembrolizumab (1)
Canada (2)